NCT02984930

Effect of Proton Pump Inhibitor and Mosapride on Acid Pocket in Gastroesophageal Reflux Disease

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Gangnam Severance Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The gastric acid pocket is believed to be the reservoir from which acid reflux events originate. The risk for acidic reflux is mainly determined by the position of the gastric acid pocket. Little is known about how changes in position and size of the acid pocket contribute to the therapeutic effect of proton pump inhibitors(PPI) plus mosapride in patients with gastroesophageal reflux disease. Investigators will conduct a prospective randomized, single blind and placebo-controlled clinical trial to evaluate the hypothesis that mosapride affecting gastric motility might reduce gastro-esophageal reflux by changing the acid pocket position and size.

Conditions

• Gastroesophageal Reflux Disease

Interventions

Type	Name	Description
DRUG	Administration of study drug (esomeprazole, mosapride)	Esomeprazole(Hanxium®) 40 mg once daily and mosapride (Gasmotin®) 5 mg t.i.d for 4 weeks.
DRUG	Administration of study drug (esomeprazole, placebo tablet)	Esomeprazole(Hanxium®) 40 mg once daily and placebo tablets that are identical to mosapride tablets t.i.d (3 times a day) for 4 weeks.
PROCEDURE	upper endoscopy, scintigraphy	After medication(4weeks), subjects will be undergo upper endoscopy and scintigraphy.

Timeline

• Start date: 2016-12-01
• Primary completion: 2018-07-01
• Completion: 2018-07-01
• First posted: 2016-12-07
• Last updated: 2016-12-07